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ABSTRACT
Making sense of rapidly evolving evidence on genetic associations is crucial to making genuine advances in
human genomics and the eventual integration of this information in the practice of medicine and public health.
Assessment of the strengths and weaknesses of this evidence, and hence the ability to synthesize it, has been
limited by inadequate reporting of results. The STrengthening the REporting of Genetic Association studies
(STREGA) initiative builds on the STrengthening the Reporting of OBservational Studies in Epidemiology
(STROBE) Statement and provides additions to 12 of the 22 items on the STROBE checklist. The additions
concern population stratification, genotyping errors, modelling haplotype variation, Hardy–Weinberg equilibrium,
replication, selection of participants, rationale for choice of genes and variants, treatment effects in studying
quantitative traits, statistical methods, relatedness, reporting of descriptive and outcome data and the volume of
data issues that are important to consider in genetic association studies. The STREGA recommendations do not
prescribe or dictate how a genetic association study should be designed, but seek to enhance the transparency
of its reporting, regardless of choices made during design, conduct or analysis.
Keywords Epidemiology, gene-disease associations, gene-environment interaction, genetics, genome-wide
association, meta-analysis, reporting recommendations, systematic review.
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The rapidly evolving evidence on genetic associations is crucial
to integrating human genomics into the practice of medicine
and public health [1,2]. Genetic factors are likely to affect the
occurrence of numerous common diseases and therefore, iden-
tifying and characterizing the associated risk (or protection)
will be important in improving the understanding of etiology
and potentially for developing interventions based on genetic
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STATEMENT
information. The number of publications on the associations
between genes and diseases has increased tremendously; with
more than 34 000 published articles, the annual number has
more than doubled between 2001 and 2008 [3,4]. Articles on
genetic associations have been published in about 1500 journals
and in several languages.
Despite the many similarities between genetic association
studies and ‘classical’ observational epidemiologic studies (that
is, cross-sectional, case-control, and cohort) of lifestyle and
environmental factors, genetic association studies present sev-
eral specific challenges including an unprecedented volume of
new data [5,6] and the likelihood of very small individual
effects. Genes may operate in complex pathways with gene-
environment and gene-gene interactions [7]. Moreover, the cur-
rent evidence base on gene-disease associations is fraught with
methodological problems [8–10]. Inadequate reporting of
results, even from well-conducted studies, hampers assessment
of a study’s strengths and weaknesses and hence the integra-
tion of evidence [11].
Although several commentaries on the conduct, appraisal
and ⁄ or reporting of genetic association studies have so far been
published [12–39], their recommendations differ. For example,
some papers suggest that replication of findings should be part
of the publication [12,13,16,17,23,26,34–36], whereas others
consider this suggestion unnecessary or even unreasonable
[21,40–44]. In many publications, the guidance has focused on
genetic association studies of specific diseases [14,15,17,19,22,
23,25,26,31–38] or the design and conduct of genetic association
studies [13–15,17,19,20,22,23,25,30–32,35,36] rather than on the
quality of the reporting.
Despite increasing recognition of these problems, the quality
of reporting genetic association studies needs to be improved
[45–49]. For example, an assessment of a random sample of 315
genetic association studies published from 2001 to 2003 found
that most studies provided some qualitative descriptions of the
study participants (for example, origin and enrolment criteria),
but reporting of quantitative descriptors such as age and gen-
der was variable [49]. In addition, completeness of reporting of
methods that allow readers to assess potential biases (for exam-
ple, number of exclusions or number of samples that could not
be genotyped) varied [49]. Only some studies described meth-
ods to validate genotyping or mentioned whether research staff
were blinded to outcome. The same problems persisted in a
smaller sample of studies published in 2006 [49]. Lack of trans-
parency and incomplete reporting have raised concerns in a
range of health research fields [11,50–53] and poor reporting
has been associated with biased estimates of effects in clinical
intervention studies [54].
The main goal of this article is to propose and justify a set of
guiding principles for reporting results of genetic association
studies. The epidemiology community has recently developed
the STrengthening the Reporting of OBservational Studies
in Epidemiology (STROBE) Statement for cross-sectional,
case-control and cohort studies [55,56]. Given the relevance of
general epidemiological principles for genetic association
studies, we propose recommendations in an extension of the
STROBE Statement called the STrengthening the REporting of
Genetic Association studies (STREGA) Statement. The
recommendations of the STROBE Statement have a strong
foundation because they are based on empirical evidence on
the reporting of observational studies and they involved
extensive consultations in the epidemiological research
community [56]. We have sought to identify gaps and areas of
controversy in the evidence regarding potential biases in
genetic association studies. With the recommendations, we
have indicated available empirical or theoretical work that has
demonstrated or suggested that a methodological feature of a
study can influence the direction or magnitude of the
association observed. We acknowledge that for many items, no
such evidence exists. The intended audience for the reporting
guideline is broad and includes epidemiologists, geneticists,
statisticians, clinician scientists and laboratory-based investiga-
tors who undertake genetic association studies. In addition, it
includes ‘users’ of such studies who wish to understand the
basic premise, design, and limitations of genetic association
studies to interpret the results. The field of genetic associations
is evolving very rapidly with the advent of genome-wide
association investigations, high-throughput platforms assessing
genetic variability beyond common single nucleotide
polymorphisms (SNPs) (for example, copy number variants,
rare variants), and eventually routine full sequencing of
samples from large populations. Our recommendations are not
intended to support or oppose the choice of any particular
study design or method. Instead, they are intended to
maximize the transparency, quality and completeness of
reporting of what was done and found in a particular study.
Methods
A multidisciplinary group developed the STREGA Statement
by using literature review, workshop presentations and discus-
sion and iterative electronic correspondence after the work-
shop. Thirty-three of 74 invitees participated in the STREGA
workshop in Ottawa, Ontario, Canada, in June, 2006. Partici-
pants included epidemiologists, geneticists, statisticians,
journal editors and graduate students.
Before the workshop, an electronic search was performed to
identify existing reporting guidance for genetic association
studies. Workshop participants were also asked to identify any
additional guidance. They prepared brief presentations on
existing reporting guidelines, empirical evidence on reporting
of genetic association studies, the development of the STROBE
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Table 1 STREGA reporting recommendations, extended from STROBE statement
Item
Item
number
STROBE
guideline
Extension for genetic
association studies (STREGA)
Title and abstract 1 (a) Indicate the study’s design with a
commonly used term in the title or
the abstract
(b) Provide in the abstract
an informative and balanced
summary of what was
done and what was found
Introduction
Background rationale 2 Explain the scientific background and
rationale for the investigation being
reported
Objectives 3 State specific objectives, including any
pre-specified hypotheses
State if the study is the first report of a
genetic association, a replication
effort or both
Methods
Study design 4 Present key elements of study design early
in the paper
Setting 5 Describe the setting, locations and relevant
dates, including periods of recruitment,
exposure, follow-up and
data collection
Participants 6 (a) Cohort study – give the eligibility criteria,
and the sources and methods of selection of
participants. Describe methods of follow-up
Case-control study – give the eligibility criteria,
and the sources and methods of case
ascertainment and control selection. Give the
rationale for the choice of cases and controls
Cross-sectional study – give the eligibility
criteria and the sources and methods of
selection of participants
Give information on the criteria and
methods for selection of subsets of
participants from a larger study,
when relevant
(b) Cohort study – for matched studies, give
matching criteria and number of exposed
and unexposed
Case-control study – for matched studies, give
matching criteria and the number of controls
per case
Variables 7 (a) Clearly define all outcomes, exposures,
predictors, potential confounders and effect
modifiers. Give diagnostic criteria,
if applicable
(b) Clearly define genetic exposures
(genetic variants) using a widely-used
nomenclature system. Identify variables
likely to be associated with population
stratification (confounding by ethnic
origin)
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Table 1 Continued
Item
Item
number
STROBE
guideline
Extension for genetic
association studies (STREGA)
Data sources ⁄measurement 8* (a) For each variable of interest, give sources
of data and details of methods of assessment
(measurement). Describe comparability of
assessment methods, if there is more than
one group
(b) Describe laboratory methods, including
source and storage of DNA, genotyping
methods and platforms (including the allele
calling algorithm used and its version), error
rates and call rates. State the laboratory ⁄ centre
where genotyping was done. Describe
comparability of laboratory methods, if there
is more than one group. Specify whether
genotypes were assigned using all of the data
from the study simultaneously or in smaller
batches
Bias 9 (a) Describe any efforts to address
potential sources of bias
(b) For quantitative outcome variables, specify
if any investigation of potential bias resulting
from pharmacotherapy was undertaken.
If relevant, describe the nature and magnitude
of the potential bias and explain what
approach was used to deal with this
Study size 10 Explain how the study size was arrived at
Quantitative variables 11 Explain how quantitative variables were
handled in the analyses. If applicable, describe
which groupings were chosen and why
If applicable, describe how effects of treatment
were dealt with
Statistical methods 12 (a) Describe all statistical methods, including
those used to control for confounding
State software version used and options
(or settings) chosen
(b) Describe any methods used to
examine subgroups and interactions
(c) Explain how missing data were addressed
(d) Cohort study – if applicable, explain how loss
to follow-up was addressed
Case-control study – if applicable, explain how
matching of cases and controls was addressed
Cross-sectional study – if applicable, describe
analytical methods taking account of sampling
strategy
(e) Describe any sensitivity analyses
(f) State whether Hardy–Weinberg equilibrium
was considered and, if so, how
(g) Describe any methods used for inferring
genotypes or haplotypes
(h) Describe any methods used to assess or
address population stratification
(i) Describe any methods used to address
multiple comparisons or to control risk of
false positive findings
(j) Describe any methods used to address
and correct for relatedness among subjects
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Table 1 Continued
Item
Item
number
STROBE
guideline
Extension for genetic
association studies (STREGA)
Results
Participants 13* (a) Report the numbers of individuals at each
stage of the study – e.g., numbers potentially
eligible, examined for eligibility, confirmed
eligible, included in the study, completing
follow-up and analysed
Report numbers of individuals in whom
genotyping was attempted and numbers of
individuals in whom genotyping was
successful
(b) Give reasons for non-participation at
each stage
(c) Consider use of a flow diagram
Descriptive data 14* (a) Give characteristics of study participants
(e.g., demographic, clinical, social) and
information on exposures and potential
confounders
Consider giving information by genotype
(b) Indicate the number of participants with
missing data for each variable of interest
(c) Cohort study – summarize follow-up time,
e.g. average and total amount
Outcome data 15* Cohort study – report numbers of outcome
events or summary measures over time
Report outcomes (phenotypes) for each
genotype category over time
Case-control study – report numbers in each
exposure category or summary measures
of exposure
Report numbers in each genotype category
Cross-sectional study – report numbers of
outcome events or summary measures
Report outcomes (phenotypes) for each
genotype category
Main results 16 (a) Give unadjusted estimates and, if applicable,
confounder-adjusted estimates and their
precision (e.g., 95% confidence intervals).
Make clear which confounders were
adjusted for and why they were included
(b) Report category boundaries when
continuous variables were categorized
(c) If relevant, consider translating estimates of
relative risk into absolute risk for a
meaningful time period
(d) Report results of any adjustments
for multiple comparisons
Other analyses 17 (a) Report other analyses performed –
e.g., analyses of subgroups and
interactions and sensitivity analyses
(b) If numerous genetic exposures (genetic
variants) were examined, summarize results
from all analyses undertaken
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Statement and several key areas for discussion that were
identified on the basis of consultations before the workshop.
These areas included the selection and participation of study
participants, rationale for choice of genes and variants
investigated, genotyping errors, methods for inferring haplo-
types, population stratification, assessment of Hardy–Weinberg
equilibrium (HWE), multiple testing, reporting of quantitative
(continuous) outcomes, selectively reporting study results, joint
effects and inference of causation in single studies. Additional
resources to inform workshop participants were the HuGENet
handbook [57,58], examples of data extraction forms from
systematic reviews or meta-analyses, articles on guideline
development [59,60] and the checklists developed for STROBE.
To harmonize our recommendations for genetic association
studies with those for observational epidemiologic studies, we
communicated with the STROBE group during the develop-
ment process and sought their comments on the STREGA draft
documents. We also provided comments on the developing
STROBE Statement and its associated explanation and
elaboration document [56].
Results
In Table 1, we present the STREGA recommendations, an
extension to the STROBE checklist [55] for genetic associa-
tion studies. The resulting STREGA checklist provides addi-
tions to 12 of the 22 items on the STROBE checklist. During
the workshop and subsequent consultations, we identified
five main areas of special interest that are specific to, or
especially relevant in, genetic association studies: genotyping
errors, population stratification, modelling haplotype varia-
tion, HWE and replication. We elaborate on each of these
areas, starting each section with the corresponding STREGA
recommendation, followed by a brief outline of the issue
and an explanation for the recommendations. Complemen-
tary information, on these areas and the rationale for addi-
tional STREGA recommendations relating to selection of
participants, choice of genes and variants selected, treatment
effects in studying quantitative traits, statistical methods,
relatedness, reporting of descriptive and outcome data, and
issues of data volume, are presented in Table 2.
Table 1 Continued
Item
Item
number
STROBE
guideline
Extension for genetic
association studies (STREGA)
(c) If detailed results are available
elsewhere, state how they
can be accessed
Discussion
Key results 18 Summarize key results with reference to
study objectives
Limitations 19 Discuss limitations of the study, taking
into account sources of potential bias or
imprecision. Discuss both direction and
magnitude of any potential bias
Interpretation 20 Give a cautious overall interpretation of results
considering objectives, limitations,
multiplicity of analyses, results from similar
studies and other relevant evidence
Generalizability 21 Discuss the generalizability (external validity)
of the study results
Other information
Funding 22 Give the source of funding and the role of the
funders for the present study and, if applicable,
for the original study on which the present
article is based
STREGA, STrengthening the REporting of Genetic Association studies; STROBE, STrengthening the Reporting of OBservational Studies in Epidemiology.
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional
studies.
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Genotyping errors
Recommendation for reporting of methods [(Table 1), item 8(b)]:
Describe laboratory methods, including source and storage of DNA,
genotyping methods and platforms (including the allele calling
algorithm used, and its version), error rates and call rates. State the
laboratory ⁄ centre where genotyping was done. Describe comparability
of laboratory methods if there is more than one group. Specify whether
genotypes were assigned using all of the data from the study
simultaneously or in smaller batches.
Recommendation for reporting of results [(Table 1), item 13(a)]:
Report numbers of individuals in whom genotyping was
attempted and numbers of individuals in whom genotyping was
successful.
Genotyping errors can occur as a result of effects of the
DNA sequence flanking the marker of interest, poor quality
or quantity of the DNA extracted from biological samples,
biochemical artefacts, poor equipment precision or equip-
ment failure, or human error in sample handling, conduct of
the array or handling the data obtained from the array [61].
A commentary published in 2005 on the possible causes and
consequences of genotyping errors observed that an increas-
ing number of researchers were aware of the problem, but
that the effects of such errors had largely been neglected
[61]. The magnitude of genotyping errors has been reported
to vary between 0.5% and 30% [61–64]. In high-throughput
centres, an error rate of 0.5% per genotype has been
observed for blind duplicates that were run on the same gel
[64]. This lower error rate reflects an explicit choice of mark-
ers for which genotyping rates have been found to be highly
repeatable and the individual polymerase chain reactions of
which have been optimized. Non-differential genotyping
errors, that is, those that do not differ systematically accord-
ing to outcome status, will usually bias associations towards
the null [65,66], just as for other non-differential errors. The
most marked bias occurs when genotyping sensitivity is
poor and genotype prevalence is high (> 85%) or, as the
corollary, when genotyping specificity is poor and genotype
prevalence is low (< 15%) [65]. When measurement of the
environmental exposure has substantial error, genotyping
errors of the order of 3% can lead to substantial under-esti-
mation of the magnitude of an interaction effect [67]. When
there are systematic differences in genotyping according to
outcome status (differential error), bias in any direction may
occur. Unblinded assessment may lead to differential mis-
classification. For genome-wide association studies of SNPs,
differential misclassification between comparison groups (for
example, cases and controls) can occur because of differ-
ences in DNA storage, collection or processing protocols,
even when the genotyping itself meets the highest possible
standards [68]. In this situation, using samples blinded to
comparison group to determine the parameters for allele
calling could still lead to differential misclassification. To
minimize such differential misclassification, it would be nec-
essary to calibrate the software separately for each group.
This is one of the reasons for our recommendation to specify
whether genotypes were assigned using all of the data from
the study simultaneously or in smaller batches.
Population stratification
Recommendation for reporting of methods [(Table 1), item 12(h)]:
Describe any methods used to assess or address population
stratification.
Population stratification is the presence within a
population of subgroups among which allele (or genotype;
or haplotype) frequencies and disease risks differ. When
the groups compared in the study differ in their propor-
tions of the population subgroups, an association between
the genotype and the disease being investigated may reflect
the genotype being an indicator identifying a population
subgroup rather than a causal variant. In this situation,
population subgroup is a confounder because it is associ-
ated with both genotype frequency and disease risk. The
potential implications of population stratification for the
validity of genetic association studies have been debated
[69–83]. Modelling the possible effect of population stratifi-
cation (when no effort has been made to address it) sug-
gests that the effect is likely to be small in most situations
[75,76,78–80]. Meta-analyses of 43 gene-disease associations
comprising 697 individual studies showed consistent associ-
ations across groups of different ethnic origin [80] and thus
provide evidence against a large effect of population strati-
fication, hidden or otherwise. However, as studies of associ-
ation and interaction typically address moderate or small
effects and hence require large sample sizes, a small bias
arising from population stratification may be important [81].
Study design (case-family control studies) and statistical
methods [84] have been proposed to address population
stratification, but so far, few studies have used these sug-
gestions [49]. Most of the early genome-wide association
studies used family-based designs or such methods as
genomic control and principal components analysis [85,86]
to control for stratification. These approaches are particu-
larly appropriate for addressing bias when the identified
genetic effects are very small (odds ratio < 1.20), as has
been the situation in many recent genome-wide association
studies [85,87–105]. In view of the debate on the potential
implications of population stratification for the validity of
genetic association studies, we recommend transparent
reporting of the methods used, or stating that none was
used, to address this potential problem. This reporting will
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enable empirical evidence to accrue about the effects of
population stratification and methods to address it.
Modelling haplotype variation
Recommendation for reporting of methods [(Table 1), item 12(g)]:
Describe any methods used for inferring genotypes or haplotypes.
A haplotype is a combination of specific alleles at neighbour-
ing genes that tends to be inherited together. There has been
considerable interest in modelling haplotype variation within
candidate genes. Typically, the number of haplotypes observed
within a gene is much smaller than the theoretical number of all
possible haplotypes [106,107]. Motivation for utilizing haplo-
types comes, in large part, from the fact that multiple SNPs
may ‘tag’ an untyped variant more effectively than a single
typed variant. The subset of SNPs used in such an approach is
called ‘haplotype tagging’ SNPs. Implicitly, an aim of haplo-
type tagging is to reduce the number of SNPs that have to be
genotyped, while maintaining statistical power to detect an
association with the phenotype. Maps of human genetic varia-
tion are becoming more complete and large scale genotypic
analysis is becoming increasingly feasible. In consequence, it is
possible that modelling haplotype variation will become more
focused on rare causal variants, because these may not be
included in the genotyping platforms.
In most current large-scale genetic association studies, data
are collected as unphased multilocus genotypes (that is, which
alleles are aligned together on particular segments of chromo-
some is unknown). It is common in such studies to use statisti-
cal methods to estimate haplotypes [108–111] and their
accuracy and efficiency have been discussed [112–116]. Some
methods attempt to make use of a concept called haplotype
‘blocks’ [117,118], but the results of these methods are sensitive
to the specific definitions of the ‘blocks’ [119,120]. Reporting of
the methods used to infer individual haplotypes and popula-
tion haplotype frequencies, along with their associated uncer-
tainties should enhance our understanding of the possible
effects of different methods of modelling haplotype variation
on study results as well as enabling comparison and syntheses
of results from different studies.
Information on common patterns of genetic variation
revealed by the International Haplotype Map (HapMap) Project
[107] can be applied in the analysis of genome-wide association
studies to infer genotypic variation at markers not typed
directly in these studies [121,122]. Essentially, these methods
perform haplotype-based tests, but make use of information on
variation in a set of reference samples (for example, HapMap)
to guide the specific tests of association, collapsing a potentially
large number of haplotypes into two classes (the allelic varia-
tion) at each marker. It is expected that these techniques will
increase power in individual studies, and will aid in combining
data across studies and even across differing genotyping
platforms. If imputation procedures have been used, it is useful
to know the method, accuracy thresholds for acceptable
imputation, how imputed genotypes were handled or weighted
in the analysis and whether any associations based on imputed
genotypes were also verified on the basis of direct genotyping
at a subsequent stage.
Hardy–Weinberg equilibrium
Recommendation for reporting of methods [(Table 1), item 12(f)]:
State whether Hardy–Weinberg equilibrium was considered and,
if so, how.
Hardy–Weinberg equilibrium has become widely accepted
as an underlying model in population genetics after Hardy
[123] and Weinberg [124] proposed the concept that genotype
frequencies at a genetic locus are stable within one generation
of random mating; the assumption of HWE is equivalent to the
independence of two alleles at a locus. Views differ on whether
testing for departure from HWE is a useful method to detect
errors or peculiarities in the data set and also the method of
testing [125]. In particular, it has been suggested that deviation
from HWE may be a sign of genotyping errors [126–128]. Test-
ing for departure from HWE has a role in detecting gross errors
of genotyping in large-scale genotyping projects such as identi-
fying SNPs for which the clustering algorithms used to call
genotypes have broken down [85,129]. However, the statistical
power to detect less important errors of genotyping by testing
for departure from HWE is low [130] and, in hypothetical data,
the presence of HWE was generally not altered by the introduc-
tion of genotyping errors [131]. Furthermore, the assumptions
underlying HWE, including random mating, lack of selection
according to genotype and absence of mutation or gene flow,
are rarely met in human populations [132,133]. In five of 42
gene-disease associations assessed in meta-analyses of almost
600 studies, the results of studies that violated HWE signifi-
cantly differed from results of studies that conformed to the
model [134]. Moreover, the study suggested that exclusion of
HWE-violating studies may result in loss of the statistical
significance of some postulated gene-disease associations and
that adjustment for the magnitude of deviation from the model
may also have the same consequence for some other gene-
disease associations. Given the differing views about the value
of testing for departure from HWE and about the test methods,
transparent reporting of whether such testing was performed
and, if so, the method used, is important for allowing the
empirical evidence to accrue.
For massive-testing platforms, such as genome-wide associa-
tion studies, it might be expected that many false-positive
violations of HWE would occur if a lenient P-value threshold
were set. There is no consensus on the appropriate P-value
threshold for HWE-related quality control in this setting. So, we
recommend that investigators state which threshold they have
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used, if any, to exclude specific polymorphisms from further
consideration. For SNPs with low minor allele frequencies, sub-
stantially more significant results than expected by chance have
been observed and the distribution of alleles at these loci has
often been found to show departure from HWE.
For genome-wide association studies, another approach that
has been used to detect errors or peculiarities in the data set
(due to population stratification, genotyping error, HWE devia-
tions or other reasons) has been to construct quantile-quantile
(Q ⁄Q) plots whereby observed association statistics or calcu-
lated P-values for each SNP are ranked in order from the small-
est to the largest and plotted against the expected null
distribution [129,130]. The shape of the curve can lend insight
into whether or not systematic biases are present.
Replication
Recommendation: State if the study is the first report of a genetic
association, a replication effort, or both (Table 1, item 3).
Articles that present and synthesize data from several
studies in a single report are becoming more common. In
particular, many genome-wide association analyses describe
several different study populations, sometimes with different
study designs and genotyping platforms and in various
stages of discovery and replication [129,130]. When data
from several studies are presented in a single original
report, each of the constituent studies and the composite
results should be fully described. For example, a discussion
of sample size and the reason for arriving at that size would
include clear differentiation between the initial group (those
that were typed with the full set of SNPs) and those that
were included in the replication phase only (typed with a
reduced set of SNPs) [129,130]. Describing the methods and
results in sufficient detail would require substantial space in
print, but options for publishing additional information on
the study online make this possible.
Discussion
The choices made for study design, conduct and data analysis
potentially influence the magnitude and direction of results of
genetic association studies. However, the empirical evidence on
these effects is insufficient. Transparency of reporting is thus
essential for developing a better evidence base (Table 2). Trans-
parent reporting helps address gaps in empirical evidence [45],
such as the effects of incomplete participation and genotyping
errors. It will also help assess the impact of currently controver-
sial issues such as population stratification, methods of
inferring haplotypes, departure from HWE and multiple testing
on effect estimates under different study conditions.
The STREGA Statement proposes a minimum checklist of
items for reporting genetic association studies. The statement
has several strengths. First, it is based on existing guidance on
reporting observational studies (STROBE). Second, it was
developed from discussions of an interdisciplinary group that
included epidemiologists, geneticists, statisticians, journal edi-
tors and graduate students, thus reflecting a broad collabora-
tive approach in terminology accessible to scientists from
diverse disciplines. Finally, it explicitly describes the rationale
for the decisions (Table 2) and has a clear plan for dissemina-
tion and evaluation.
The STREGA recommendations are available at: http://
www.strega-statement.org/. We welcome comments, which
will be used to refine future versions of the recommendations.
We note that little is known about the most effective ways to
apply reporting guidelines in practice and that therefore it has
been suggested that editors and authors collect, analyse and
report their experiences in using such guidelines [135]. We con-
sider that the STREGA recommendations can be used by
authors, peer reviewers and editors to improve the reporting of
genetic association studies. We invite journals to endorse STRE-
GA, for example by including STREGA and its Web address in
their Instructions for Authors and by advising authors and peer
reviewers to use the checklist as a guide. It has been suggested
that reporting guidelines are most helpful if authors keep the
general content of the guideline items in mind as they write
their initial drafts, then refer to the details of individual items
as they critically appraise what they have written during the
revision process [135]. We emphasize that the STREGA report-
ing guidelines should not be used for screening submitted
manuscripts to determine the quality or validity of the study
being reported. Adherence to the recommendations may make
some manuscripts longer and this may be seen as a drawback
in an era of limited space in a print journal. However, the ability
to post-information on the Web should alleviate this concern.
The place in which supplementary information is presented
can be decided by authors and editors of the individual journal.
We hope that the recommendations stimulate transparent
and improved reporting of genetic association studies. In turn,
better reporting of original studies would facilitate the synthe-
sis of available research results and the further development of
study methods in genetic epidemiology with the ultimate goal
of improving the understanding of the role of genetic factors in
the cause of diseases.
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